Agalsidase Beta
- CAS Codes:104138-64-9
- PHARMGKB ID:104138-64-9
Table of contents
- Brand Names
- Chemistry
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Fabrazyme; Belgium: Fabrazyme; Bulgaria: Fabrazyme; Cyprus: Fabrazyme; Czech Republic: Fabrazyme; Denmark: Fabrazyme; Estonia: Fabrazyme; Finland: Fabrazyme; France: Fabrazyme; Germany: Fabrazyme; Greece: Fabrazyme; Hungary: Fabrazyme; Ireland: Fabrazyme; Italy: Fabrazyme; Latvia: Fabrazyme; Lithuania: Fabrazyme; Luxembourg: Fabrazyme; Malta: Fabrazyme; Netherlands: Fabrazyme; Poland: Fabrazyme; Portugal: Fabrazyme; Romania: Fabrazyme; Slovakia: Fabrazyme; Slovenia: Fabrazyme; Spain: Fabrazyme; Sweden: Fabrazyme; UK: Fabrazyme.
North America
Canada: Fabrazyme; USA: Fabrazyme.
Asia
Japan: Fabrazyme.
Drug combinations
Chemistry
Agalsidase Beta: C~2029~H~3080~N~544~O~587~S~27~ (subunit protein moiety reduced). α-Galactosidase (human clone λAG^18^ isoenzyme A subunit protein moiety reduced), glycoform β. CAS-104138-64-9.
Pharmacologic Category
Enzymes. (ATC-Code: A16AB04).
Pharmacologic Category
Mechanism of action
Catalyzes the hydrolysis of globotriaosylceramide (Gb-3) and other glycosphingolipids.
Therapeutic use
Replacement therapy for Fabry disease.
Pregnancy and lactiation implications
Animal reproduction studies have not demonstrated adverse effects. There are as yet no adequate studies in pregnant women. Use with caution during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to agalsidase beta or any component of the formulation.
Warnings and precautions
Patients might develop IgG and IgE antibody formation. Infusion-related reactions are common (may be severe). Use with caution in cardiovascular disease (increased risk of complications from infusion reactions).